VistaGen fails phase 2 depression trial, sparking stock rout

A phase 2 trial of VistaGen Therapeutics’ AV-101 in major depressive disorder has missed its primary endpoint, sending shares in the nanocap biotech down 64% premarket. VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.